Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Preventive or late administration of anti-NGF therapy attenuates tumor-induced nerve sprouting, neuroma formation, and cancer pain.

Jimenez-Andrade JM, Ghilardi JR, Castañeda-Corral G, Kuskowski MA, Mantyh PW.

Pain. 2011 Nov;152(11):2564-74. doi: 10.1016/j.pain.2011.07.020. Epub 2011 Sep 9.

2.

Blockade of nerve sprouting and neuroma formation markedly attenuates the development of late stage cancer pain.

Mantyh WG, Jimenez-Andrade JM, Stake JI, Bloom AP, Kaczmarska MJ, Taylor RN, Freeman KT, Ghilardi JR, Kuskowski MA, Mantyh PW.

Neuroscience. 2010 Dec 1;171(2):588-98. doi: 10.1016/j.neuroscience.2010.08.056. Epub 2010 Sep 20.

3.

A blocking antibody to nerve growth factor attenuates skeletal pain induced by prostate tumor cells growing in bone.

Halvorson KG, Kubota K, Sevcik MA, Lindsay TH, Sotillo JE, Ghilardi JR, Rosol TJ, Boustany L, Shelton DL, Mantyh PW.

Cancer Res. 2005 Oct 15;65(20):9426-35.

4.

Administration of a tropomyosin receptor kinase inhibitor attenuates sarcoma-induced nerve sprouting, neuroma formation and bone cancer pain.

Ghilardi JR, Freeman KT, Jimenez-Andrade JM, Mantyh WG, Bloom AP, Kuskowski MA, Mantyh PW.

Mol Pain. 2010 Dec 7;6:87. doi: 10.1186/1744-8069-6-87.

5.

Pathological sprouting of adult nociceptors in chronic prostate cancer-induced bone pain.

Jimenez-Andrade JM, Bloom AP, Stake JI, Mantyh WG, Taylor RN, Freeman KT, Ghilardi JR, Kuskowski MA, Mantyh PW.

J Neurosci. 2010 Nov 3;30(44):14649-56. doi: 10.1523/JNEUROSCI.3300-10.2010.

6.

Breast cancer-induced bone remodeling, skeletal pain, and sprouting of sensory nerve fibers.

Bloom AP, Jimenez-Andrade JM, Taylor RN, Castañeda-Corral G, Kaczmarska MJ, Freeman KT, Coughlin KA, Ghilardi JR, Kuskowski MA, Mantyh PW.

J Pain. 2011 Jun;12(6):698-711. doi: 10.1016/j.jpain.2010.12.016. Epub 2011 Apr 15.

7.

Sensory and sympathetic nerve fibers undergo sprouting and neuroma formation in the painful arthritic joint of geriatric mice.

Jimenez-Andrade JM, Mantyh PW.

Arthritis Res Ther. 2012 May 1;14(3):R101. doi: 10.1186/ar3826.

8.

Clinical perspectives on preclinical models of bone pain: questions and promises.

Portenoy R.

Pain. 2011 Nov;152(11):2455-6. doi: 10.1016/j.pain.2011.08.008. Epub 2011 Aug 24. No abstract available.

PMID:
21868166
9.

Anti-NGF therapy profoundly reduces bone cancer pain and the accompanying increase in markers of peripheral and central sensitization.

Sevcik MA, Ghilardi JR, Peters CM, Lindsay TH, Halvorson KG, Jonas BM, Kubota K, Kuskowski MA, Boustany L, Shelton DL, Mantyh PW.

Pain. 2005 May;115(1-2):128-41.

PMID:
15836976
10.

NGF blockade at early times during bone cancer development attenuates bone destruction and increases limb use.

McCaffrey G, Thompson ML, Majuta L, Fealk MN, Chartier S, Longo G, Mantyh PW.

Cancer Res. 2014 Dec 1;74(23):7014-23. doi: 10.1158/0008-5472.CAN-14-1220. Epub 2014 Oct 6.

11.

Nerve growth factor links oral cancer progression, pain, and cachexia.

Ye Y, Dang D, Zhang J, Viet CT, Lam DK, Dolan JC, Gibbs JL, Schmidt BL.

Mol Cancer Ther. 2011 Sep;10(9):1667-76. doi: 10.1158/1535-7163.MCT-11-0123. Epub 2011 Jul 12.

12.

Effects of a monoclonal antibody raised against nerve growth factor on skeletal pain and bone healing after fracture of the C57BL/6J mouse femur.

Koewler NJ, Freeman KT, Buus RJ, Herrera MB, Jimenez-Andrade JM, Ghilardi JR, Peters CM, Sullivan LJ, Kuskowski MA, Lewis JL, Mantyh PW.

J Bone Miner Res. 2007 Nov;22(11):1732-42.

13.

Nerve growth factor sequestering therapy attenuates non-malignant skeletal pain following fracture.

Jimenez-Andrade JM, Martin CD, Koewler NJ, Freeman KT, Sullivan LJ, Halvorson KG, Barthold CM, Peters CM, Buus RJ, Ghilardi JR, Lewis JL, Kuskowski MA, Mantyh PW.

Pain. 2007 Dec 15;133(1-3):183-96. Epub 2007 Aug 10.

PMID:
17693023
14.

Targeting nerve growth factor in pain: what is the therapeutic potential?

Watson JJ, Allen SJ, Dawbarn D.

BioDrugs. 2008;22(6):349-59. doi: 10.2165/0063030-200822060-00002. Review.

PMID:
18998753
15.

The majority of myelinated and unmyelinated sensory nerve fibers that innervate bone express the tropomyosin receptor kinase A.

Castañeda-Corral G, Jimenez-Andrade JM, Bloom AP, Taylor RN, Mantyh WG, Kaczmarska MJ, Ghilardi JR, Mantyh PW.

Neuroscience. 2011 Mar 31;178:196-207. doi: 10.1016/j.neuroscience.2011.01.039. Epub 2011 Jan 26.

16.

Exuberant sprouting of sensory and sympathetic nerve fibers in nonhealed bone fractures and the generation and maintenance of chronic skeletal pain.

Chartier SR, Thompson ML, Longo G, Fealk MN, Majuta LA, Mantyh PW.

Pain. 2014 Nov;155(11):2323-36. doi: 10.1016/j.pain.2014.08.026. Epub 2014 Sep 6.

17.

Neuroplasticity of sensory and sympathetic nerve fibers in a mouse model of a painful arthritic joint.

Ghilardi JR, Freeman KT, Jimenez-Andrade JM, Coughlin KA, Kaczmarska MJ, Castaneda-Corral G, Bloom AP, Kuskowski MA, Mantyh PW.

Arthritis Rheum. 2012 Jul;64(7):2223-32. doi: 10.1002/art.34385.

18.

Targeting cells of the myeloid lineage attenuates pain and disease progression in a prostate model of bone cancer.

Thompson ML, Jimenez-Andrade JM, Chartier S, Tsai J, Burton EA, Habets G, Lin PS, West BL, Mantyh PW.

Pain. 2015 Sep;156(9):1692-702. doi: 10.1097/j.pain.0000000000000228.

19.

Effect of administration of antibodies against nerve growth factor in a rat model of muscle injury.

Suzuki M, Inage K, Sakuma Y, Orita S, Yamauchi K, Suzuki T, Suzuki M, Kubota G, Oikawa Y, Sainoh T, Sato J, Fujimoto K, Shiga Y, Abe K, Kanamoto H, Takahashi K, Ohtori S.

Injury. 2016 Mar;47(3):609-12. doi: 10.1016/j.injury.2015.11.026. Epub 2015 Nov 24.

PMID:
26653267
20.

Antibodies to nerve growth factor reverse established tactile allodynia in rodent models of neuropathic pain without tolerance.

Wild KD, Bian D, Zhu D, Davis J, Bannon AW, Zhang TJ, Louis JC.

J Pharmacol Exp Ther. 2007 Jul;322(1):282-7. Epub 2007 Apr 12.

Supplemental Content

Support Center